BAXTER Company Profile

What is the competitive landscape for BAXTER

BAXTER has two hundred and nineteen approved drugs.

There are twenty-five US patents protecting BAXTER drugs. There are three tentative approvals on BAXTER drugs.

There are forty-nine patent family members on BAXTER drugs in nineteen countries and three hundred and thirty-six supplementary protection certificates in seventeen countries.

Summary for BAXTER

International Patents:	49
US Patents:	25
Tradenames:	303
Ingredients:	132
NDAs:	219
Patent Litigation for BAXTER:	See patent lawsuits for BAXTER
PTAB Cases with BAXTER as patent owner:	See PTAB cases with BAXTER as patent owner

Drugs and US Patents for BAXTER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	020734-017	Sep 29, 1997		RX	No	No
Baxter Hlthcare	DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	dextrose; sodium chloride	INJECTABLE;INJECTION	016689-001	Approved Prior to Jan 1, 1982	AP	RX	No	No
Baxter Hlthcare Corp	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER	magnesium sulfate	INJECTABLE;INJECTION	211965-001	Aug 11, 2020	AP	RX	No	No
Baxter Hlthcare Corp	NOURESS	cysteine hydrochloride	SOLUTION;INTRAVENOUS	212535-001	Dec 13, 2019		DISCN	Yes	No	11,648,262		Y
Baxter Hlthcare Corp	CYCLOPHOSPHAMIDE	cyclophosphamide	SOLUTION;INTRAVENOUS	217651-002	Jun 28, 2023		RX	Yes	Yes
Baxter Hlthcare	PREMASOL 10% IN PLASTIC CONTAINER	amino acids	INJECTABLE;INJECTION	075880-002	Jun 19, 2003		RX	No	No
Baxter Hlthcare Corp	FLUMAZENIL	flumazenil	INJECTABLE;INJECTION	076755-001	Oct 12, 2004	AP	RX	No	No

Expired US Patents for BAXTER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-003	Oct 10, 1992	5,696,172
Baxter Hlthcare	CYTOXAN (LYOPHILIZED)	cyclophosphamide	INJECTABLE;INJECTION	012142-009	Dec 10, 1985	4,537,883
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982	3,535,425
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998	6,207,661
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-001	Feb 24, 1998	7,915,229
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982	3,535,388
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992	4,882,452

Paragraph IV (Patent) Challenges for BAXTER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Inhalation	99.90%		2008-09-11
	Injection	10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags		2014-01-31

International Patents for BAXTER Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	4591858
Japan	2012072160
Mexico	352459
Australia	2017376960
South Korea	20110010742
New Zealand	589290
Denmark	3554474

Supplementary Protection Certificates for BAXTER Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1441735	SPC/GB08/020	United Kingdom		PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
0933372	SPC/GB08/018	United Kingdom		PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
1280520	C01280520/01	Switzerland		PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 60565 01.02.2012
1559427	C 2013 020	Romania		PRODUCT NAME: MIRABEGRON SAU O SARE A ACESTUIA(2-(2-AMINO-1,3-TRIAZOL-4-IL)-N-[4-(2-{[(2R)-2-HIDROXI9/014; DATE OF NATIONAL AUTHORISATION: 20121220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/809/001 - EU/1/12/809/014; DATE OF FIRST AUTHORISATION IN EEA: 20121220 -2-FENILETIL]AMINO}ETIL)FENIL]ACETAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/12/809/001 - EU/1/12/80
3494972	202440019	Slovenia		PRODUCT NAME: DOLUTEGRAVIR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING SODIUM DOLUTEGRAVIR, AND LAMIVUDINE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1370; DATE OF NATIONAL AUTHORISATION: 20190701; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1506193	SPC/GB14/044	United Kingdom		PRODUCT NAME: RIOCIGUAT, I.E. METHYL N-(4,6-DIAMINO-2-(1-(2-FLUOROBENZYL)-1H-PYRAZOLO (3,4-B)PYRIDIN-3-YL)-5-PYRIMIDINYL(METHYL)CARBAMATE,OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE THEREOF.; REGISTERED: UK EU/1/13/907 20140331
1087960	2011C/028	Belgium		PRODUCT NAME: ERIBULIN; AUTHORISATION NUMBER AND DATE: EU/1/11/678/001 20110317

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Baxter Hlthcare
• Baxter Hlthcare Corp